🇺🇸 FDA
Pipeline program

Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab

ACT16482-06

Phase 2 small_molecule active

Quick answer

Dexamethason 4 mg JENAPHARM®, evorpacept, Isatuximab, Dexamethason 8 mg JENAPHARM®, Isatuximab for Cancer is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).

Program details

Company
Sanofi Pharma Bristol-Myers Squibb
Indication
Cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials